HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Loss of the platelet activating factor receptor in mice augments PMA-induced inflammation and cutaneous chemical carcinogenesis.

Abstract
Although platelet-activating factor (PAF) is a well-known acute inflammatory mediator, little is known regarding the role of PAF in chronic inflammation. Phorbol esters are known to stimulate PAF production. Moreover, the ability of repeated applications of phorbol esters to induce a sustained inflammatory response is crucial to their tumorigenic activity. We therefore examined whether PAF acts as a mediator of phorbol ester-induced inflammation and tumorigenesis. While PAF receptor knockout mice (PAFR(-/-)) showed an expected but modest reduction in the acute inflammatory response to phorbol 12-myristate 13-acetate (PMA), these mice exhibited a surprising increase in inflammation following chronic PMA application. This increased inflammation was documented by a number of findings that included: increased skin thickness, increased myeloperoxidase activity and expression and increased expression of known inflammatory mediators. Interestingly, vehicle-treated PAFR(-/-) mice also exhibited modest increases in levels of inflammatory markers. This suggests that the platelet activating factor receptor (PAFR) acts to suppress chronic inflammation in response to other stimuli, such as barrier disruption. The idea that chronic PAFR activation is anti-inflammatory was documented by repetitive topical PAFR agonist administration that resulted in reduced myeloperoxidase activity in skin. We next utilized a 7,12-dimethylbenz(a)anthracene/PMA carcinogenesis protocol to demonstrate that PAFR(-/-) mice exhibit significantly increased tumor formation and malignant progression compared with wild-type control mice. These studies provide evidence for two important, unexpected and possibly interrelated pathological roles for the PAFR: first, the PAFR acts to suppress PMA-induced chronic inflammation; secondly, the PAFR acts to suppress neoplastic development in response to chemical carcinogens.
AuthorsRavi P Sahu, Amal A Kozman, Yongxue Yao, Sonia C DaSilva, Samin Rezania, Kellie C Martel, Simon J Warren, Jeffrey B Travers, Raymond L Konger
JournalCarcinogenesis (Carcinogenesis) Vol. 33 Issue 3 Pg. 694-701 (Mar 2012) ISSN: 1460-2180 [Electronic] England
PMID22223848 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Platelet Activating Factor
  • Platelet Membrane Glycoproteins
  • Receptors, G-Protein-Coupled
  • platelet activating factor receptor
  • 9,10-Dimethyl-1,2-benzanthracene
  • Tetradecanoylphorbol Acetate
Topics
  • 9,10-Dimethyl-1,2-benzanthracene (pharmacology)
  • Animals
  • Cell Transformation, Neoplastic (chemically induced)
  • Inflammation (chemically induced)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Platelet Activating Factor (metabolism)
  • Platelet Membrane Glycoproteins (genetics, metabolism)
  • Receptors, G-Protein-Coupled (genetics, metabolism)
  • Signal Transduction
  • Skin (drug effects, metabolism, pathology)
  • Skin Neoplasms (chemically induced)
  • Tetradecanoylphorbol Acetate (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: